ADAM17 and COVID-19: First, and quite logically, one can advocate the potential negative impact of COVID-19 on malignant disease evolution, including detrimental treatment restrictions.5 However, more consideration should also be given to the repercussions of cancer on COVID-19, including the impact of cancer treatments, and particular attention should thus be paid to the modulation of the above-highlighted intrinsic key factors which are both ADAM17 and TMPRSS2 (Fig. 1).